Stockreport

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer [Yahoo! Finance]

Purple Biotech Ltd. - American Depositary Shares  (PPBT) 
PDF A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the contro [Read more]